Clozapine‐induced gastroesophageal rumination in 22q11.2 Deletion Syndrome. A case report on gastroesophageal side effects management without renouncing clozapine's effectiveness

Despite entailing more severe and uncommon side effects in 22q11.2DS compared to idiopathic schizophrenia, we strongly believe that clozapine should continue to be considered the gold standard for all treatment‐resistant schizophrenia, even in 22qDS.

Zapisane w:
Opis bibliograficzny
Wydane w:Clin Case Rep
Główni autorzy: Accinni, Tommaso, Frascarelli, Marianna, Ghezzi, Francesco, Panzera, Alessia, Buzzanca, Antonino, Fanella, Martina, Di Bonaventura, Carlo, Carlone, Luca, Girardi, Nicoletta, Pasquini, Massimo, Di Fabio, Fabio
Format: Artigo
Język:Inglês
Wydane: John Wiley and Sons Inc. 2021
Hasła przedmiotowe:
Case Reports
Dostęp online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8142464/
https://ncbi.nlm.nih.gov/pubmed/34084508
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ccr3.4134
Etykiety: Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy